(Q37699953)

English

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

scientific article published on 26 February 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

22 August 2017

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study (English)

1 reference

Europe PubMed Central

22 August 2017

0 references

Alzheimer's disease

0 references

William E. Klunk

object named as

William E Klunk

6

0 references

object named as

Nick C Fox

4

0 references

David J. Brooks

object named as

David J Brooks

2

0 references

8

object named as

Kaj Blennow

1 reference

Europe PubMed Central

22 August 2017

object named as

Martin N Rossor

3

0 references

1

object named as

Juha O Rinne

1 reference

Europe PubMed Central

22 August 2017

10

object named as

Aren A Okello

1 reference

Europe PubMed Central

22 August 2017

9

object named as

Jerome Barakos

1 reference

Europe PubMed Central

22 August 2017

12

object named as

Enchi Liu

1 reference

Europe PubMed Central

22 August 2017

Michael Grundman

17

object named as

Michael Grundman

1 reference

Europe PubMed Central

22 August 2017

author name string

Roger Bullock

5

1 reference

Europe PubMed Central

22 August 2017

Chester A Mathis

7

1 reference

Europe PubMed Central

22 August 2017

Sofia Rodriguez Martinez de Liano

11

1 reference

Europe PubMed Central

22 August 2017

Martin Koller

13

1 reference

Europe PubMed Central

22 August 2017

Keith M Gregg

14

1 reference

Europe PubMed Central

22 August 2017

Dale Schenk

15

1 reference

Europe PubMed Central

22 August 2017

Ronald Black

16

1 reference

Europe PubMed Central

22 August 2017

publication date

26 February 2010

1 reference

Europe PubMed Central

22 August 2017

Lancet Neurology

1 reference

Europe PubMed Central

22 August 2017

9

1 reference

Europe PubMed Central

22 August 2017

363-372

1 reference

Europe PubMed Central

22 August 2017

4

1 reference

Europe PubMed Central

22 August 2017

Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970043-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunotherapy reduces vascular amyloid-beta in PDAPP mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970043-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970043-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970043-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970043-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970043-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970043-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970043-0

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro characterization of Pittsburgh compound-B binding to Lewy bodies.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970043-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970043-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970043-0

7 January 2021

based on heuristic

inferred from DOI database lookup

“Mini-mental state”

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970043-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathological verification of ischemic score in differentiation of dementias.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970043-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970043-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970043-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A new rating scale for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970043-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Functional disability in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970043-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A neuropsychological test battery for use in Alzheimer disease clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970043-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The Clinical Dementia Rating (CDR): current version and scoring rules

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970043-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970043-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970043-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970043-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970043-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970043-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970043-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The binding of 2-(4'-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970043-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantifying amyloid beta-peptide (Abeta) aggregation using the Congo red-Abeta (CR-abeta) spectrophotometric assay.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970043-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970043-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970043-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970043-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970043-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970043-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970043-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970043-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1474-4422(10)70043-0

1 reference

Europe PubMed Central

22 August 2017

1 reference

Europe PubMed Central

22 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37699953&oldid=1743199769"